Premium
Cyclophosphamide, adriamycin, and cisdiamminedichloroplatinum (II) in the treatment of advanced nonsquamous cell head and neck cancer
Author(s) -
Creagan Edward T.,
Woods John E.,
Schutt Allan J.,
O'Fallon Judith R.
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19831201)52:11<2007::aid-cncr2820521106>3.0.co;2-t
Subject(s) - medicine , head and neck , cyclophosphamide , head and neck cancer , oncology , cancer , chemotherapy , surgery
Sixteen patients with regionally advanced or disseminated nonsquamous cell (NSC) head and neck cancer received a monthly combination chemotherapy regimen of cyclophosphamide (C), Adriamycin (A), and cis‐diamminedichloroplatinum (II) (P), or P, as a single agent administered by either bolus or 24‐hour infusion technique. Fifteen patients had received extensive prior surgery and/or radiation therapy. Three patients had prior chemotherapy. A response rate of 50% was achieved (8/16); there were 2 complete regressions and 6 partial regressions. The estimated median time to progression (TTP) for the entire group of 16 patients was 6.0 months and the estimated median survival was 14.0 months. Seven of 8 responders have progressed, with a median TTP of 10.7 months. Virtually all patients experienced alopecia as well as nausea and vomiting, which was more pronounced with the bolus administration of P. Myelosuppression was tolerable; there was no clinically significant renal impairment. Cancer 52:2007‐2010, 1983.